Using stereotactic radiotherapy for treating thoracic tumors
Official title: Safety and Efficacy of SBRT in the Treatment of Thoracic Malignant Tumors at Different Sites
Run by Peking University Third Hospital · NCT05349552 · Data updated 2026-11-12
This study tests if a special type of radiation therapy can safely treat chest tumors that are 5cm or smaller while protecting nearby healthy tissue.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 120 (estimated) |
| Sponsor | Peking University Third Hospital Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Status | Recruiting |
| Started | May 1, 2022 |
| Main results expected | April 30, 2025 |
| Study ends | April 30, 2027 |
| Registry record updated | December 27, 2023 |
| Trial ID | NCT05349552 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include patients with a pathological diagnosis of malignant tumors located in specific areas of the chest, with lesions measuring 5cm or less.
✕Probably not a fit
Patients with poor pulmonary function, severe underlying health conditions, or those unable to cooperate with treatment may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates the safety and efficacy of stereotactic body radiation therapy (SBRT) for malignant tumors located in different areas of the chest. It categorizes tumors based on their proximity to critical structures such as the chest wall and bronchial tree, aiming to understand how these factors influence treatment outcomes and toxicity. The research focuses on patients with tumors that are 5cm or smaller and assesses the effectiveness of SBRT in providing localized control while minimizing damage to surrounding healthy tissue. By analyzing various tumor types, the study seeks to optimize treatment protocols for thoracic cancers.
Why it matters
Potential benefit: If successful, this study could enhance the safety and effectiveness of radiotherapy for patients with thoracic malignancies.
How similar studies have gone: Other studies have shown promising results with SBRT in lung cancer treatment, indicating potential success for this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Pathological diagnosis was malignant tumor. * The location of the target lesion belongs to one of five types and the lesion diameter is ≤ 5cm. * There is no extensive systemic metastasis or although there is metastasis, the metastasis have been controlled by previous treatment. * KPS\>70, no serious or uncontrolled underlying diseases, such as severe or uncontrolled hypertension, diabetes, cardiovascular and cerebrovascular diseases and organ dysfunction, and patients are expected to be tolerated by radiotherapy. Exclusion Criteria: * Poor basic pulmonary function or symptom correlation caused by various reasons, unable to lie flat or cooperate with treatment. * The general condition is poor, and the expected survival time is less than 3 months. * Psychiatric patients or poor compliance, unable to cooperate to complete treatment. * For other reasons, the researcher believes that it is not suitable to participate in this trial.
Where it's running
-
Peking University Third Hospital
Beijing, Beijing Municipality, China Recruiting
Study contacts
- Study coordinator: Zhe Ji, M.D.
- Email: aschoff@163.com
- Phone: 008618710002823
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Analysis of outcomes and side effects in patients receiving radiation therapy
This study looks at the results and side effects of radiation therapy in patients at Winterthur Cantonal Hospital to see how treatment can be improved for future patients.
-
Primary tumor removal with targeted lymph node removal plus radiation for biliary tract cancer with lymph node spread
This phase II study tests whether removing the main tumor and select nearby lymph nodes, followed by postoperative radiation, helps patients with biliary tract cancer and lymph node metastases.
-
Tributyrin as a dietary supplement to help prevent radiation-induced rectal injury during rectal cancer chemoradiation
This study tests whether adding tributyrin to standard chemoradiotherapy helps prevent acute radiation-induced rectal injury in people with locally advanced rectal cancer.
-
Targeted Induction Therapy for Stage III Unresectable EGFR Mutant NSCLC
This trial tests a targeted induction approach using fumetinib with platinum-based chemotherapy and concurrent radiochemotherapy in adults with unresectable stage III EGFR-mutant NSCLC to see if this combo can improve outcomes before possible surgery.
-
Virtual vs in-person follow-up visits after radiotherapy
This study tests whether telehealth follow-ups during radiotherapy are practical and satisfactory for patients and physicians, compared to in-person visits.
-
LUCINAE Registry: Thoracic Cancers in Pregnancy
This international registry collects data to see how thoracic cancers, including lung cancer, are managed and what outcomes look like for pregnant people and their babies.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.